Product nameDyLight® 800 Conjugation Kit (Fast) - Lightning-Link®
DyLight® 800 Conjugation Kit / DyLight® 800 Labeling Kit (ab201806) uses a simple and quick process for DyLight 800 labeling / conjugation of antibodies. It can also be used to conjugate other proteins or peptides. Learn about our antibody labeling kits and their advantages.
To conjugate an antibody to DyLight® 800 using this kit:
- add modifier to antibody and incubate for 15 mins
- add quencher and incubate for 5 mins
The DyLight® 800 conjugated antibody can be used immediately in WB, ELISA, IHC etc. No further purification is required and 100% of the antibody is recovered for use.
Learn about buffer compatibility below; for incompatible buffers and low antibody concentrations, use our rapid antibody purification and concentration kits. Use the FAQ to learn more about the technology, or about conjugating other proteins and peptides to DyLight® 800.
Custom size conjugation kits up to 100 mg are available on demand. Please contact us to discuss your requirements.
This product is manufactured by Expedeon, an Abcam company, and was previously called Lightning-Link® Rapid DyLight® 800 Labeling Kit. 329-0005 is the same as the 100 µg size. 329-0010 is the same as the 3 x 100 ug size. 329-0030 is the same as the 3 x 10 ug size. 329-0015 is the same as the 1 mg size.
Amount and volume of antibody for conjugation to DyLight® 800
Kit size Recommended
amount of antibody1
amount of antibody
3 x 10 µg 3 x 10 µg 3 x 20 µg 3 x 10 µL 100 µg 1 x 100 µg 1 x 200 µg 1 x 100 µL 3 x 100 µg 3 x 100 µg 3 x 200 µg 3 x 100 µL 1 mg 1 x 1 mg 1 x 2 mg 1 x 1 mL
1 Using the maximum amount of antibody may result in less labelling per antibody.
2 Ideal antibody concentration is 1 mg/ml. 0.5 - 1 mg/ml can be used if the maximum antibody volume is not exceeded. Antibodies > 2 mg/ml or < 0.5 mg/ml should be diluted /concentrated.
Buffer Requirements for Conjugation
Buffer should be pH 6.5-8.5.
Compatible buffer constituents
If a concentration is shown, then the constituent should be no more than the concentration shown. If several constituents are close to the limit of acceptable concentration, then this can inhibit conjugation.
50mM / 0.6% Tris1 0.1% BSA2 50% glycerol 0.1% sodium azide PBS Potassium phosphate Sodium chloride HEPES Sucrose Sodium citrate EDTA Trehalose
1 Tris buffered saline is almost always ≤ 50 mM / 0.6%
2 BSA can also interfere with the use of the conjugated antibody in tissue staining.
Incompatible buffer constituents
Thiomerosal Proclin Glycine Arginine Glutathione DTT
Only purified antibodies are suitable for use, ie. where other proteins, peptides, or amino acids are not present: antibodies in ascites fluid, serum or hybridoma culture media are incompatible.
Storing and handling conjugation kits
Lyophilized Lightning-Link® components are hygroscopic.
Kits are intentionally shipped at ambient temperature with silica gel to avoid exposure to moisture. Upon receipt, store the kit frozen and protect from moisture. Before opening the outer container, allow the lyophilized components to reach room temperature to minimize condensation.
DyLight® is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
Storage instructionsStore at -20°C. Please refer to protocols.
Components 1 mg 100 µg 3 x 10 µg 3 x 100 µg ab274034 - Dylight® 800 Conjugation Mix 1 x 1mg 1 x 100µg 3 x 10µg 3 x 100µg ab273994 - Modifier reagent 1 x 200µl 1 x 200µl 1 x 200µl 1 x 200µl ab273995 - Quencher reagent 1 x 200µl 1 x 200µl 1 x 200µl 1 x 200µl
Ou, Li et al used DyLight® 800 Conjugation Kit - Lightning-Link® (ab201806) as part of examining murine Hurler syndrome. They used the kit to conjugate DyLight® 800 to anti-GAPDH antibody for use in western blot.
In Vivo ZFN-Mediated Insertion of hIDUA at the Albumin Locus Results in Expression of Active Enzyme in MPS I Mouse Hepatocytes. Expression of hIDUA in mouse liver protein extracts 1 or 4 months post-treatment. Each lane represents an individual mouse. GAPDH is shown as a loading control.
This illustration demonstrates a general procedure and will slightly vary dependent on the conjugate used.
ab201806 has been referenced in 5 publications.
- Wang F et al. Loss of Bcl-3 delays bone fracture healing through activating NF-κB signaling in mesenchymal stem cells. J Orthop Translat 35:72-80 (2022). PubMed: 36186660
- Fu Y et al. Expression of different L1 isoforms of Mastomys natalensis papillomavirus as mechanism to circumvent adaptive immunity. Elife 9:N/A (2020). PubMed: 32746966
- Yasuda M et al. AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction. Mol Ther Methods Clin Dev 18:607-619 (2020). PubMed: 32775495
- Ou L et al. ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome. Mol Ther 27:178-187 (2019). PubMed: 30528089
- Laoharawee K et al. Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing. Mol Ther 26:1127-1136 (2018). PubMed: 29580682